Ryotaro Nakamura, M.D.
Areas of Expertise
- Hematologic Malignancies
- Myelodysplastic Syndrome
- Aplastic Anemia
- Hematopoietic Stem Cell (Bone Marrow) Transplantation
- Graft vs Host Disease
Other Languages Spoken
Since joining City of Hope in 2002, Ryotaro Nakamura, M.D. has been at the forefront of cutting-edge research in stem cell transplantation and development of cancer vaccines. Among his promising projects: A study indicating that bone marrow transplants may be effective in treating systemic mastocytosis, a rare blood disease with no known cure, and the use of vaccines to replace antivirals which can often spawn deadly infections.
Dr. Nakamura trained in Japan and served a fellowship in hematology and oncology at the National Institutes of Health in Bethesda, MD, before arriving at City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute, which includes the Judy and Bernard Briskin Center for Multiple Myeloma Research, Toni Stephenson Lymphoma Center and Gehr Family Center for Leukemia Research.
- 2009 to present - Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
- 2011 to present - Member, City of Hope Comprehensive Cancer Center's Hematologic Malignancies Program
- 2008 to present - Associate Chair, Cancer Protocol Review and Monitoring Committee, City of Hope
- 2002 to present - Staff Physician, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
- 2012 to present - Steering Committee member, BMT-Clinical Trial network
- 2004 to 2009, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
- 1991 - Kumamoto University School of Medicine , M.D.
- 1998 to 2001 - Fellow, Hematology/Oncology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
- 1995 to 1998 - Resident, Thomas Jefferson University Hospital, Philadelphia, PA
- 1993 to 1994 - Resident and Chief Resident (1994) in Internal Medicine, Iizuka Hospital, Fukuoka, Japan
- 1991 to 1993 - Resident, Kumamoto University Hospital, Kumamoto, Japan
When a Sister Becomes a Lifesaver
October 09, 2017
CMVPepVax vaccine reduces complications post stem cell transplants
December 23, 2015
CMV vaccine reduces complications after stem cell transplants
December 23, 2015
Bone marrow transplant may be answer to incurable, fatal blood disease
September 04, 2014
Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy.
- American Medical Association
- American Society of Hematology
- American College of Physicians
- Japanese Society of Internal Medicine
- American Society for Blood and Marrow Transplantation
- 2008 to 2009 - Recipient, Tim Nesvig Lymphoma Fellowship Award
- 2000 - Fellows Travel Award for the Tenth Annual Mayo Clinic Jacksonville Hematology/Oncology Reviews. Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for treatment of chronic refractory autoimmune thrombocytopenia (AITP): Jacksonville, FL